Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.41 |
| ▸ | DNTT | P04053 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28256306 | 0.87 | POLA1 (0.41) | POLA1DNTTPOLB | |
| SCHEMBL10875328 | 0.83 | POLA1 (0.47) | POLA1DNTTPOLBGAA | |
| SCHEMBL6276544 | 0.83 | POLA1 (0.47) | POLA1DNTTPOLBGAA | |
| SCHEMBL2975191 | 0.75 | POLA1 (0.39) | POLA1DNTTPOLB | |
| SCHEMBL11324268 | 0.73 | POLA1 (0.42) | POLA1DNTTPOLB | |
| SCHEMBL3796115 | 0.72 | POLA1 (0.43) | POLA1DNTTPOLB | |
| SCHEMBL11341998 | 0.72 | POLA1 (0.47) | POLA1DNTTPOLB | |
| SCHEMBL27578070 | 0.70 | POLA1 (0.38) | POLA1DNTTPOLBGAA | |
| SCHEMBL27282491 | 0.69 | DNTT (0.32) | POLA1DNTTALDH1A1 | |
| SCHEMBL3007350 | 0.67 | POLA1 (0.31) | POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227540-A1 | TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES | TAPUAE PARTNERSHIP (NZ) | 2009-09-10 | — | — | US | disclosed |
| EP-1965958-A1 | TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES | Tapuae Partnership (NZ) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007064236-A1 | TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES | TAPUAE PARTNERSHIP (NZ) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227540-A1 | TREATMENT OF WOOD BASED ON NOVEL FORMULATIONS OF BORATRANES | BLVRB, BCHE, MGAM | POLA1 4436/4885DNTT 1069/4885POLB 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.